Beyond the Hype: Why Novo Nordisk's Diabetes Empire Remains a Compounding Machine
While Wall Street obsesses over GLP-1 weight-loss drugs, Novo Nordisk's foundational diabetes business continues to deliver robust growth and exceptional returns on assets, presenting a durable investment thesis often overshadowed by the obesity narrative.